ALX Oncology

Also different combo Clin2 (fast track) head & neck cancer (partner: MercK), Clin2 (fast track) gastric cancer (partner: Lilly), Clin1 urothelial cancer; 2 trials Clin1 breast cancer (one partnered: Zymeworks), Clin0 multiple myeloma; ALTA-002 Clin0 oncology

ALX Oncology is developing immunotherapies for cancer treatment. CD47 is a cell surface protein expressed on cancer cells that signals to evade detection by the immune system. ALX’s approach revolves around inhibiting CD47 and the “don’t eat me” signal, known as checkpoint inhibition, to further stimulate the immune response against the cancer. The inhibitors are designed by ALX to have high affinity for CD47 and to avoid the limitations caused by hematologic toxicities seen in other immunotherapies. ALX believes their lead product candidate, evorpacept (ALX148), has a wide therapeutic window and can be combined with anti-cancer agents. Their current programs are focused on targeting CD47 across various oncology indications.

Jobs: